DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 20, 2018, reports the cash position of DBV Technologies S.A. as of December 31, 2017. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company is headquartered in Montrouge, France, with shares traded on Euronext Paris (DBV) and Nasdaq (DBVT).
Key Financial Metrics
| Metric | Value (as of Dec 31, 2017) | Value (as of Dec 31, 2016) |
|---|---|---|
| Cash and Cash Equivalents | €137.9 million | €256.5 million |
| Outstanding Shares | 24,990,822 | Filing text does not provide a clear value |
| Fully Diluted Shares | 28,300,361 | Filing text does not provide a clear value |
The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt for the reporting period.
Material Changes
- Cash Position: Cash and cash equivalents decreased by €118.6 million, representing a 46.2% decline from €256.5 million in 2016 to €137.9 million in 2017.
- Share Count: The company reported 24,990,822 outstanding ordinary shares and 28,300,361 fully diluted shares as of December 31, 2017.
Outlook, Risks, and Management Commentary
Management highlighted ongoing clinical trials for Viaskin Peanut and Viaskin Milk, as well as preclinical development for Viaskin Egg. The company is also pursuing a human proof-of-concept study for Viaskin Milk to treat Eosinophilic Esophagitis and exploring applications in vaccines. The filing does not contain specific forward-looking financial guidance, risk factors, or contingencies beyond the general description of clinical development stages.
Key Facts for Investor Verification
- Verify the specific operational and R&D expenses driving the €118.6 million reduction in cash reserves during 2017.
- Confirm the current status and timelines of the Viaskin Peanut and Viaskin Milk clinical trials.
- Review the full 2017 annual report (Form 20-F) for comprehensive revenue, expense, and debt data not included in this cash position update.
- Assess the impact of the fully diluted share count (28.3 million) on potential future dilution.